Gilead Sciences (GILD) Stock Price, News & Analysis

Company Overview

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19. Through its Kite subsidiary, Gilead develops and markets cell therapies, including Yescarta and Tecartus, for certain blood cancers. Trodelvy is another key product used in the treatment of certain breast and urothelial cancers.

Founded in 1987, Gilead has expanded through internal research, partnerships and acquisitions, including its 2017 acquisition of Kite Pharma, a developer of chimeric antigen receptor T-cell therapies. The company is headquartered in Foster City, California, and distributes its medicines through a global commercial and research network. Daniel O’Day serves as Gilead’s chairman and chief executive officer.

Key Stats

• Today's Range: $143.67 to $145.91
• 50-Day Range: $129.31 to $151.22
• 52-Week Range: $108.46 to $157.29
• Volume: 1.20 million shs
• Average Volume: 6.93 million shs
• Market Capitalization: $179.06 billion
• P/E Ratio: N/A
• Dividend Yield: 2.27%
• Price Target: $158.78
• Consensus Rating: Moderate Buy

Gilead Sciences Stock Analysis - MarketRank™

Gilead Sciences scored higher than 78% of companies evaluated by MarketBeat, and ranked 141st out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Gilead Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 23 buy ratings, 5 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Gilead Sciences is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Gilead Sciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Gilead Sciences are expected to grow in the coming year, from ($0.48) to $9.87 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Gilead Sciences is -54.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Gilead Sciences is -54.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Gilead Sciences has a P/B Ratio of 7.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.88% of the float of Gilead Sciences has been sold short.

Short Interest Ratio / Days to Cover

Gilead Sciences has a short interest ratio ("days to cover") of 3.24, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Gilead Sciences has recently decreased by 4.93%, indicating that investor sentiment is improving.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Gilead Sciences pays a meaningful dividend of 2.17%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Gilead Sciences has been increasing its dividend for 10 years.

Dividend Sustainability

Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 33.23% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.91

News Sentiment

Gilead Sciences has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 36 news articles for Gilead Sciences this week, compared to 13 articles on an average week.

Search Interest

Only 23 people have searched for GILD on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.

MarketBeat Follows

30 people have added Gilead Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Gilead Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,495,820.00 in company stock.

Percentage Held by Insiders

0.30% of the stock of Gilead Sciences is held by insiders.

Percentage Held by Institutions

83.67% of the stock of Gilead Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 6/29 Dividend: 6/15/2026
• Ex-Dividend for 6/29 Dividend: 6/15/2026
• Dividend Payable: 6/29/2026
• Last Earnings: 8/03/2026
• Today: 9/10/2026
• 12th Annual Cantor Fitzgerald Global Healthcare Conference: 9/10/2026
• Record date for 9/29 Dividend: 9/15/2026
• Ex-Dividend for 9/29 Dividend: 9/15/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/15/2026
• Dividend Payable: 9/29/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GILD
• CIK: 882095
• Web: www.gilead.com
• Phone: (650) 574-3000
• Fax: 650-578-9264
• Employees: 17,000
• Year Founded: 1987

Price Target and Rating

• Average Price Target for Gilead Sciences: $158.78
• High Price Target: $180.00
• Low Price Target: $123.00
• Potential Upside/Downside: +10.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 29 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $8.51 billion
• Net Margins: -10.64%
• Pretax Margin: -6.42%
• Return on Equity: -2.11%
• Return on Assets: -0.75%

Debt

• Debt-to-Equity Ratio: 2.03
• Current Ratio: 1.27
• Quick Ratio: 1.09

Sales & Book Value

• Annual Sales: $30.46 billion
• Price / Sales: 5.87
• Cash Flow: $10.29 per share
• Price / Cash Flow: 14.01
• Book Value: $18.23 per share
• Price / Book: 7.91

Miscellaneous

• Outstanding Shares: 1,239,955,000
• Free Float: 1,236,235,000
• Market Cap: $178.71 billion
• Optionable: Optionable
• Beta: 0.33